Global Oncology Biosimilars Market 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights

PART 05: Overview of cancer

• Epidemiology
• Economic burden of cancer

PART 06: Biosimilars industry

• Comparison between biosimilars and generic small molecules
• Factors influencing biologics and biosimilars
• Biosimilars: business and pricing strategy
• Factors affecting the uptake of biosimilars
• Biosimilar opportunities
• Growth of biosimilars 2014– 2020
• Market penetration of originators and biosimilars in different regions
• Current and future trends in global oncology biosimilars market
• Challenges for new entrants

PART 07: Global pharmaceutical market

• Market size and forecast
• Global biosimilars market

PART 08: Market landscape

• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by end-user

• Hospitals
• Retail pharmacies

PART 10: Market segmentation by application

• Cancer treatment drugs
• Supportive care drugs

PART 11: Geographical segmentation

• Global oncology biosimilar drugs market by geographical segmentation 2015-2020
• Oncology biosimilars market in EMEA
• Oncology biosimilars market in APAC
• Oncology biosimilars market in Americas

PART 12: Key leading regions

• US
• Europe
• Japan
• India
• China

PART 13: Market drivers

• Rise in number of patent expiries
• Increase in prevalence of cancer
• Growing aging population
• Promising drug pipeline
• Need for cost-effective treatment
• Favorable government regulations

PART 14: Impact of drivers

PART 15: Market challenges

• Risks related to failure of drugs in market
• Multiple manufacturing complexities
• Reluctance among physicians to prescribe biosimilar products
• Complicated regulatory process
• Limited availability of biosimilar products
• Risk of side effects

PART 16: Impact of drivers and challenges

PART 17: Market trends

• Emergence of biosimilars
• Outsourcing of biosimilar manufacturing activities
• Rising number of strategic collaborations
• Increase in cancer awareness
• Rise in R&D

PART 18: Vendor landscape

• Competitive scenario
• Biocon
• Celltrion
• Dr. Reddy's Laboratories
• F Hoffmann-La Roche
• Hospira
• Mylan
• Sandoz
• Other prominent vendors

PART 19: Appendix

• List of abbreviations

PART 20: Explore Technavio